Investors

Investors 2017-11-02T11:57:23+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

ASX: Dimerix rights issue discussion

Dimerix announced last week that it would offer shareholders the opportunity to participate an Entitlement Offer to raise up to $5.5m. Funds raised would drive the company's lead drug development program, DMX-200 to its nearest [...]

Entitlement Offer Booklet

Read the Entitlement Offer Booklet here.

Entitlement Offer Cleansing Notice

Read the notice here.

Read More

Media Coverage

ASX: Dimerix rights issue discussion

Dimerix announced last week that it would offer shareholders the opportunity to participate an Entitlement Offer to raise up to $5.5m. Funds raised would drive the company's lead drug development program, DMX-200 to its nearest [...]

Entitlement Offer Booklet

Read the Entitlement Offer Booklet here.

Entitlement Offer Cleansing Notice

Read the notice here.

Read More

Analyst Reports

Baker Young DXB Flash Note November 2017

Read this here. 

Bioshares November 2017

View their report here. 

ASX Announcements – Baker Young Initiates Coverage of DXB

Baker Young Stockbrokers have initiated coverage of Dimerix Limited. The research report is available here: BY-DXB Research Report - Oct - Initiation of Coverage - BUY.

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with [...]

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates